« Back to Record
Citation APA

Burstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., Abbas, R., Powell, C., Turnbull, K., Vermette, J., Zacharchuk, C., & Badwe, R. (2010). Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of clinical oncology, 28(8), 1301-1307. doi:10.1200/JCO.2009.25.8707


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/53552

Burstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., Abbas, R., Powell, C., Turnbull, K., Vermette, J., Zacharchuk, C., & Badwe, R. (2010). Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of clinical oncology, 28(8), 1301-1307. doi:10.1200/JCO.2009.25.8707